Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
US5804370A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 2, 1995 |
| Grant date | Sep 8, 1998 |
| Priority date | — |
| Expiry date | Nov 2, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to a method for determining the extent of sepsis and/or an infection in a human or animal patient by detecting the amount of an antigen indicative of such infection. The amount of the antigen is detected in a patient blood derived test sample containing blood cell fractions. The method comprises: PA1 i) incubating the test sample with an amount of test antibodies specific to the antigen indicative of sepsis and/or infection to form antibody/antigen complexes; PA1 ii) allowing the antibody/antigen complexes to interact with the white blood cell fractions which results in the production of oxidants; PA1 iii) introducing to either steps i) or ii) a chemiluminescent compound to the test sample; PA1 iv) allowing the oxidants to react with the chemiluminescent compounds to emit luminescent light from the test sample; PA1 v) measuring the amount of emitted light over a predetermined period; and PA1 vi) correlating extent of sepsis and/or infection by comparison of the measured amount of emitted light of the test sample with measured amount of light emitted by a control sample which is treated the same as the test sample for steps i) to v) except that in step i) contr…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.